Business Context and Reporting Period
This Form 8-K filing by Sotera Health Company (SHC) covers events occurring on May 11, 2026, and May 13, 2026. The report details a secondary offering of common stock by selling stockholders and the subsequent termination of the Company's Stockholders Agreement.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The transaction described is a secondary offering where the Company did not issue new shares and received no proceeds.
- Shares Sold: 31,838,253 shares of Common Stock.
- Offering Price: $15.168 per share.
- Company Proceeds: $0 (The Company did not receive any proceeds from the sale).
- Underwriter: Goldman Sachs & Co. LLC.
Material Changes Versus Prior Period
The primary material change is the exit of the Company's prior private equity sponsors, Warburg Pincus LLC and GTCR LLC (collectively, the "Sponsors").
- Ownership Change: Following the sale, the Sponsors no longer own any Common Stock.
- Governance Change: The Stockholders Agreement, dated November 19, 2020, terminated on May 13, 2026. This ended the Sponsors' special corporate governance rights, including the right to designate directors to the Board.
- Board Composition: Directors previously designated by the Sponsors are not required to resign and may serve until the end of their terms.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the structural changes noted. The transaction was executed without the participation of the Company's executive officers.
Key Facts for Investor Verification
- Verify the exact number of shares sold (31,838,253) and the price per share ($15.168) in the Underwriting Agreement (Exhibit 1.1).
- Confirm that the Company received zero proceeds from this transaction, as it was a secondary sale by existing stockholders.
- Review the termination of the Stockholders Agreement to understand the removal of special governance rights held by Warburg Pincus and GTCR.
- Check the current Board composition to identify which directors were previously designated by the Sponsors and their remaining terms.